Hereditary Angioedema (HAE) — A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
Citation(s)
A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects